Alexza Completes Enrollment In AZ-001 Phase IIb Clinical Trial In Patients With Migraine Headaches

Thu, 14 Dec 2006 02:00 PM EST

... Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has completed patient enrollment in its Phase IIb clinical trial of AZ-001 (Staccato(R) prochlorperazine) in patients with migraine headaches. AZ-001 is an inhalation product candidate being developed for the acute treatment of migraine headaches. [click link for full article] ...